Introduction
Doxazosin is a long acting ␣ 1 -adrenoceptor antagonist, used in the treatment of essential hypertension and/or benign prostatic hyperplasia (BPH). [1] [2] [3] These effects are complemented, by favourable changes in serum lipids, haemostatic factors and insulin sensitivity. [1] [2] [3] Hypertensive patients are at a risk of thrombotic events. 4 It follows that it would be an advantage for antihypertensive drugs to possess anti-thrombotic properties. 4 In this context, there is evidence that doxazosin inhibits platelet activation. [5] [6] [7] However, doxazosin did not inhibit serotonin (5-hydroxytryptamine; 5-HT)-induced platelet aggregation in humans. [5] [6] [7] This is a relevant topic for further research because patients with peripheral vascular disease (PVD) or diabetes mellitus have elevated circulating levels of 5-HT. [8] [9] [10] [11] These conditions are associated with a high prevalence of hypertension and vascular events. 12 PVD is associated with platelet hyperactivity. 13 Elevated plasma levels of 5-HT were also associated with an increased incidence of graft reocclusion after infrainguinal by-pass surgery. 9 These associations may be attributed to the harmful properties of 5-HT that include stimulating vascular muscle proliferation and platelet aggregation as well as inducing vasoconstriction in atheromatous coronary vessels. [9] [10] [11] Platelets are the main (95%) store of circulating 5-HT. [9] [10] [11] This bioamine is released from activated platelets 8 and can induce platelet shape change (PSC), an early phase of platelet activation, which is essentially aspirin resistant.
14-27 PSC can be induced by considerably lower concentrations of 5-HT than aggregation (0.06-0.5 vs 10.0 mol/l, respectively). 15 Similarly, PSC can be inhibited by lower concen-
Journal of Human Hypertension
trations of antagonists when compared to aggregation. 15 We therefore used this technique to reassess the effect of doxazosin on 5-HT-induced platelet activation in human platelets. This investigation is based on the evidence that ␣-adrenoceptor antagonists also block 5-HT receptors.
28,29

Patients and methods
Venous blood was collected in 3.8% citrate (1 part citrate to 9 parts blood) from healthy volunteers (n = 8; five males, three females with a median age of 32 years, range: 26-57). Volunteers denied taking any drugs for at least 2 weeks prior to sampling. The volunteers were fasting overnight and were all nonsmokers. The citrated blood was centrifuged at 160 g for 15 min at room temperature. The platelet rich plasma (PRP) was then carefully collected with a Pasteur pipette. Aliquots of PRP (450 l), in siliconised glass cuvettes, were placed in a Chronology dual channel optical aggregometer (Coulter Electronics, Luton, Beds, UK) and kept at 37°C for 15 min prior to the start of the experiment. [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] Agonists (5-HT, 0.06-0.5; ADP, 0.1-0.2 mol/l or U46619, a TXA 2 analogue, 0.025-0.05 mol/l) were added (as 10-50 l volumes) to PRP and stirred at 1000 rpm. These agonists concentrations and sampling times were determined in previous studies; they generate the most reproducible results. [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] We adjusted the concentration of agonists to obtain a middle range response that could be either inhibited or enhanced. [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] The volumes of distilled water (control) added to samples were matched to those of the agonist (as 10-50 l volumes).
PRP (100 l aliquots) was removed and mixed with 400 l of fixative, (4% aqueous glutaraldehyde) at 30 sec, 60 sec (see 'Results' for details) after adding the agonists. This sample was further diluted 400-fold in Isoton II (Coulter Electronics). These samples were then processed by a Coulter counter ZM (electrical impedance method using a 70-m diameter sampling tube orifice) coupled to a C-256 channelyser (Coulter Electronics). The analyser sample 'window' was set between 2.67 and 19.12 fl. [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] The counter was calibrated using latex-particles of 9 fl (Coulter Electronics). For particle analysis, data were accumulated to a maximum of 500 platelets in each of the 256 channels. The median platelet volume (MPV) was the volume of the channel on each side of which 50% of the platelet population is distributed. [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] The increase in MPV was taken as representing the PSC. [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] The platelet count was monitored throughout the experiment to exclude PRP samples where significant (Ͼ5%) aggregation occurred.
PRP was also incubated for 4 min with doxazosin (final concentration 0.33 mol/l, a concentration similar to therapeutic plasma levels) 1 prior to the addition of each of the above-mentioned agonists. This was carried out to determine whether doxazosin could inhibit PSC. We also established if this inhibition was specific for any of the agonists. Because a harmful synergistic effect of various agonists may occur in vivo, we examined the effect of doxazosin on a combination of two such agonists at sub-maximal concentrations (ADP, 0.04 mol/l + 5-HT, 0.06 mol/l-see Table 1 ).
Doxazosin mesylate (mol. wt. 547.6) was prepared by dissolving the compound in distilled water. Saline solutions, or other media-containing chloride ions, were avoided as this result in the precipitation of the less soluble chloride salt of doxazosin. 
Statistical analysis and presentation of the results
The results are presented as median and interquartile range. Comparisons are by non-parametric analysis (paired Wilcoxon tests, two-tailed).
Results
Effect of doxazosin on 5-HT-induced PSC
The 5-HT-induced increase in MPV was significantly inhibited (P = 0.007 and P = 0.008, at 30 sec and 60 sec, respectively) by doxazosin ( Table 2) . Doxazosin alone did not affect the MPV (incubation time: up to 4 min).
Effect of doxazosin on ADP-and U46619-induced PSC
The increase in MPV induced by ADP and U46619 was not inhibited by doxazosin (Table 3) .
Effect of doxazosin on a combination of ADP + 5-HT-induced PSC
Doxazosin inhibited PSC induced by a combination of ADP + 5-HT (Table 1) . In a representative experiment, the combined effect of ADP + 5-HT became equivalent to the MPV response seen with ADP or 5-HT alone (at 30 and 60 sec). Statistical analysis: 5HT 30 sec vs doxazosin+5HT 30 sec: P = 0.007; 5HT 60 sec vs doxazosin+5HT 60 sec: P = 0.008. a The dose of 5HT (0.06-0.5 M) was selected to produce a middle range increase in MPV. This response could then be inhibited or enhanced. 
Discussion
Doxazosin inhibited 5-HT-induced platelet activation (represented by PSC) in samples collected from healthy volunteers. These findings are of clinical interest because PSC, an early phase of platelet activation, is essentially aspirin resistant. [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] [30] [31] [32] Furthermore, the other harmful effects of 5-HT in the vasculature (see 'Introduction') and elsewhere (eg, bladder or prostate) 29 may be inhibited by doxasosin. These possibilities deserve investigation.
Because in vivo several agonists may act synergistically, 5 we evaluated PSC after adding 5-HT + ADP. The increase in MPV caused by this combination became equivalent to that seen with ADP or 5-HT alone. We conclude that the contribution of 5-HT to the synergistic effect was inhibited since doxazosin did not influence ADP-induced PSC.
Doxazosin may only inhibit the 5-HT 2 receptordependent actions of 5-HT because these receptors mediate platelet activation 15 and doxazosin did not alter ADP-or U46619-induced PSC. However, doxazosin significantly reduced 29 Doxazosin also influences platelet calcium mobilisation. 5, 33 This mechanism may account for the inhibition, by high concentrations (30 M) of doxazosin, of adrenaline-induced aggregation potentiated by collagen, ADP or serotonin 5 and possibly for the PSC effect we observed. However, the considerably lower concentration of doxazosin we used (0.33 M) and the agonist specificity of this effect, the binding of doxazosin to 5-HT 3 receptors 29 and the 5-HT antagonist activity of other ␣-blockers 28,29 favours a receptor-mediated mode of action. Furthermore, we previously showed that ketanserin, a 5-HT 2 antagonist which also has some ␣-blocker activity, inhibits 5-HT-induced PSC. 15 Others demonstrated that doxazosin inhibited ADP-induced platelet aggregation. 6, 7 This finding is not in agreement with our results or those of others. 5 This discrepancy is probably the result of inappropriate methodology 5 used in the earlier studies. 6, 7 The sensitivity of the PSC technique was demonstrated by the fact that others, 5 did not detect an inhibitory effect of doxazosin on 5-HT-induced aggregation despite adding considerably higher concentrations of this drug than we did (30 vs 0.33 mol/l).
Our results should be interpreted after considering that, in humans, the circulating levels of 5-HT are in the 4 -15 nmol/l range. 10 Nevertheless, near therapeutic levels of doxazosin blocked PSC induced by considerably higher 5-HT concentrations (up to 0.50 mol/l).
Our findings are limited because they were carried out in vitro and in samples obtained from healthy subjects. Furthermore, we rely on a single index of platelet function.
Platelets contribute to thrombosis and atherosclerosis and inhibiting platelet activity is of clinical importance. 34 Several antihypertensive drugs alter haemostatic factors. 19, [35] [36] [37] [38] [39] This additional beneficial action may influence prescribing. 4 The antiplatelet action of antihypertensives may vary in specificity. For example, doxazosin inhibits 5-HT-mediated platelet activation whereas losartan 19 inhibits the activation induced by angiotensin II and thromboxane A 2 . These differences may gain importance because of the need to use of multiple drugs to treat hypertension. 12 The variability in the inhibitory specificity of different antihypertensives may be relevant if several agonists mediate platelet activation in vivo. These drugs may then exert a synergistic inhibitory action on platelets. Future studies should assess this possibility as well as the effect of doxazosin on 5-HT-induced responses.
